AzarGen Biotechnologies Overview
- Year Founded
-
2003
- Status
-
Private
- Employees
-
4
- Latest Deal Type
-
2ndary - Private
AzarGen Biotechnologies General Information
Description
Developer of human therapeutic proteins designed to increase the survivability of premature-born infants. The company's therapeutic proteins are made using advanced plant-based genetic engineering and synthetic biology techniques and it also offers a plant-based expression technology that comprises optimal combinations of novel synthetic promoters, combined with enhancer and purification components, enabling medical professionals to provide drugs with superior clinical efficacy at low cost to improve the health status of citizens and address unmet medical needs.
Contact Information
Website
www.azargen.co.zaCorporate Office
- Launchlab Hammanshand Road
- Stellenbosch, Western Cape 7600
- South Africa
Corporate Office
- Launchlab Hammanshand Road
- Stellenbosch, Western Cape 7600
- South Africa
AzarGen Biotechnologies Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 4. Secondary Transaction - Private | 01-May-2024 | Completed | Clinical Trials - Phase 1 | |||
| 3. Accelerator/Incubator | 27-Jun-2016 | Completed | Clinical Trials - Phase 1 | |||
| 2. Later Stage VC (Series B) | 07-Jan-2016 | $3.1M | $3.1M | Completed | Clinical Trials - Phase 1 | |
| 1. Accelerator/Incubator | Completed | Clinical Trials - Phase 1 |
AzarGen Biotechnologies Patents
AzarGen Biotechnologies Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2015262984-A1 | Synthetic promoter construct for transgene expression | Inactive | 19-May-2014 | ||
| EP-3146053-A1 | Synthetic promoter construct for transgene expression | Inactive | 19-May-2014 | ||
| US-20150329869-A1 | Synthetic promoter construct for transgene expression | Active | 19-May-2014 | ||
| US-9670497-B2 | Synthetic promoter construct for transgene expression | Active | 19-May-2014 | ||
| WO-2015177659-A1 | Synthetic promoter construct for transgene expression | Inactive | 19-May-2014 | C12N15/8216 |
AzarGen Biotechnologies Signals
AzarGen Biotechnologies FAQs
-
When was AzarGen Biotechnologies founded?
AzarGen Biotechnologies was founded in 2003.
-
Where is AzarGen Biotechnologies headquartered?
AzarGen Biotechnologies is headquartered in Stellenbosch, South Africa.
-
What is the size of AzarGen Biotechnologies?
AzarGen Biotechnologies has 4 total employees.
-
What industry is AzarGen Biotechnologies in?
AzarGen Biotechnologies’s primary industry is Biotechnology.
-
Is AzarGen Biotechnologies a private or public company?
AzarGen Biotechnologies is a Private company.
-
What is AzarGen Biotechnologies’s current revenue?
The current revenue for AzarGen Biotechnologies is .
-
How much funding has AzarGen Biotechnologies raised over time?
AzarGen Biotechnologies has raised $3.1M.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process